BG62841B1 - Използване на бензидамин за лечение на патологичнисъстояния, причинени от туморнекрозен фактор - Google Patents

Използване на бензидамин за лечение на патологичнисъстояния, причинени от туморнекрозен фактор Download PDF

Info

Publication number
BG62841B1
BG62841B1 BG100385A BG10038596A BG62841B1 BG 62841 B1 BG62841 B1 BG 62841B1 BG 100385 A BG100385 A BG 100385A BG 10038596 A BG10038596 A BG 10038596A BG 62841 B1 BG62841 B1 BG 62841B1
Authority
BG
Bulgaria
Prior art keywords
benzidamine
acid addition
physiologically acceptable
acceptable acid
tnf
Prior art date
Application number
BG100385A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG100385A (bg
Inventor
Valerio Cioli
Original Assignee
Angelini Ricerche S.P.A. Societa'consortile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angelini Ricerche S.P.A. Societa'consortile filed Critical Angelini Ricerche S.P.A. Societa'consortile
Publication of BG100385A publication Critical patent/BG100385A/bg
Publication of BG62841B1 publication Critical patent/BG62841B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
BG100385A 1993-07-27 1996-02-26 Използване на бензидамин за лечение на патологичнисъстояния, причинени от туморнекрозен фактор BG62841B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT93MI001673A IT1276040B1 (it) 1993-07-27 1993-07-27 Uso della benzidamina nel trattamento di stati patologici causati dal tnf
PCT/EP1994/002343 WO1995003799A1 (en) 1993-07-27 1994-07-14 Use of benzydamine in the treatment of pathological conditions caused by tnf

Publications (2)

Publication Number Publication Date
BG100385A BG100385A (bg) 1996-09-30
BG62841B1 true BG62841B1 (bg) 2000-09-29

Family

ID=11366694

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100385A BG62841B1 (bg) 1993-07-27 1996-02-26 Използване на бензидамин за лечение на патологичнисъстояния, причинени от туморнекрозен фактор

Country Status (25)

Country Link
US (1) US6300358B1 (it)
EP (1) EP0711163B1 (it)
JP (1) JP3587851B2 (it)
CN (1) CN1085528C (it)
AT (1) ATE207353T1 (it)
AU (1) AU692458B2 (it)
BG (1) BG62841B1 (it)
CA (1) CA2167926C (it)
CZ (1) CZ285864B6 (it)
DE (1) DE69428797T2 (it)
DK (1) DK0711163T3 (it)
ES (1) ES2163450T3 (it)
HU (1) HU226805B1 (it)
IT (1) IT1276040B1 (it)
LV (1) LV11524B (it)
NO (1) NO308195B1 (it)
NZ (1) NZ269563A (it)
PL (1) PL312741A1 (it)
PT (1) PT711163E (it)
RO (1) RO117149B1 (it)
RU (1) RU2160102C2 (it)
SI (1) SI0711163T1 (it)
SK (1) SK281895B6 (it)
WO (1) WO1995003799A1 (it)
ZA (1) ZA945431B (it)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101199515B (zh) * 2007-12-21 2010-12-08 重庆市莱美药物技术有限公司 盐酸苄达明洗剂及其制备方法
WO2010093588A1 (en) * 2009-02-10 2010-08-19 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
HUE028220T2 (en) * 2009-07-08 2016-12-28 Acraf The use of benzidamine in the treatment of p40-dependent diseases
MD4291C1 (ro) * 2013-12-27 2015-02-28 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Preparat medicamentos pentru tratamentul otitelor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (it) * 1963-08-09
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release

Also Published As

Publication number Publication date
AU692458B2 (en) 1998-06-11
CZ285864B6 (cs) 1999-11-17
PL312741A1 (en) 1996-05-13
ES2163450T3 (es) 2002-02-01
ITMI931673A0 (it) 1993-07-27
EP0711163A1 (en) 1996-05-15
ZA945431B (en) 1995-02-28
SI0711163T1 (en) 2001-12-31
NZ269563A (en) 2001-03-30
SK10596A3 (en) 1997-03-05
DE69428797D1 (de) 2001-11-29
NO308195B1 (no) 2000-08-14
RO117149B1 (ro) 2001-11-30
JPH09500385A (ja) 1997-01-14
ATE207353T1 (de) 2001-11-15
LV11524A (lv) 1996-10-20
BG100385A (bg) 1996-09-30
ITMI931673A1 (it) 1995-01-27
IT1276040B1 (it) 1997-10-24
HUT73500A (en) 1996-08-28
AU7386194A (en) 1995-02-28
CN1130872A (zh) 1996-09-11
CA2167926C (en) 2004-12-21
DK0711163T3 (da) 2001-11-26
NO960347L (no) 1996-03-07
SK281895B6 (sk) 2001-09-11
DE69428797T2 (de) 2002-04-18
EP0711163B1 (en) 2001-10-24
CZ25596A3 (en) 1996-07-17
LV11524B (en) 1996-12-20
HU226805B1 (en) 2009-10-28
NO960347D0 (no) 1996-01-26
PT711163E (pt) 2002-04-29
WO1995003799A1 (en) 1995-02-09
CN1085528C (zh) 2002-05-29
CA2167926A1 (en) 1995-02-09
US6300358B1 (en) 2001-10-09
RU2160102C2 (ru) 2000-12-10
JP3587851B2 (ja) 2004-11-10

Similar Documents

Publication Publication Date Title
US6291527B1 (en) Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
CA2078221C (en) Pharmaceutical compositions comprising taurolidine and/or taurultam
US5008242A (en) Treatment of inflammation using 1-antichymotrypsin
WO2004052362A1 (en) Combination of an dpp-iv inhibitor and a ppar-alpha compound
KR100322042B1 (ko) 비쇼그렌증후군성구강건조증치료제
EP0491018A1 (en) Use of taurolidine and/or taurultam for the treatment of tumours
SK7502002A3 (en) Pharmaceutical combinations
EP0923371A1 (en) Pharmaceutical compositions comprising tyrphostins
JPH10511978A (ja) アルツハイマー病の治療用薬剤
BG62841B1 (bg) Използване на бензидамин за лечение на патологичнисъстояния, причинени от туморнекрозен фактор
JPH0640915A (ja) 自己免疫疾患処置のための医薬組成物
ZA200106199B (en) Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity.
Valeriano-Marcet et al. Myonecrosis and myofibrosis as complications of sickle cell anemia
FI105075B (fi) Kombinaatioinjektiovalmisteen käyttö
US20200170990A1 (en) Method for treating schnitzler's syndrome
US5530003A (en) Pharmaceutical compositions for curing rheumatism
KR100514009B1 (ko) 1,2,4-벤조트리아진옥사이드제제
EP0551180B1 (en) Use of bucillamine for the manufacture of a medicament for the treatment of cystinuria
JP2788340B2 (ja) 炎症治療剤
US4436732A (en) Medicated compound for treating diseases infected by virus of the herpes group
KR100508623B1 (ko) 마크롤라이드 화합물의 신규한 용도
EP0256629A2 (en) Tolrestat or a salt thereof as an immuno-stimulating agent
SK2802002A3 (en) The use of dexrazoxane, an article comprising dexrazoxane, method for treating psoriasis and method for producing a drug